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Background: Human papillomavirus type 16 (HPV 16) E2 protein is a multifunctional DNA-binding protein. HPV 16
E2 regulates many biological responses, including DNA replication, gene expression, and apoptosis. The purpose of
this study was to investigate the relationship among the receptor for globular heads of the human C1q (gC1qR)
gene expression, HPV 16 E2 transfection and apoptosis regulation in human cervical squamous carcinoma cells
(C33a and SiHa).
Methods: gC1qR expression was examined in C33a and SiHa cells using real-time PCR and Western blot analysis.
Apoptosis of C33a and SiHa cells was assessed by flow cytometry. C33a and SiHa cell viability, migration and
proliferation were detected using the water-soluble tetrazolium salt (WST-1) assay, a transwell assay and
3H-thymidine incorporation into DNA (3H-TdR), respectively.
Results: C33a and SiHa cells that were transfected with a vector encoding HPV 16 E2 displayed significantly
increased gC1qR gene expression and p38 mitogen-activated protein kinase (p38 MAPK)/ c-jun N-terminal kinase
(JNK) activation as well as up-regulation of cellular apoptosis, which was abrogated by the addition of gC1qR small
interfering RNA (siRNA). Furthermore, the changes in C33a and SiHa cell viability, migration and proliferation that
were observed upon HPV 16 E2 transfection were abrogated by SB203580 (a p38 MAPK inhibitor) or SP600125
(a JNK inhibitor) treatment.
Conclusion: These data support a mechanism whereby HPV 16 E2 induces apoptosis by silencing the gC1qR gene
or inhibiting p38 MAPK/JNK signalling in cervical squamous cell carcinoma.
Keywords: Human papillomavirus type 16 (HPV 16) E2, Receptor for the globular heads of the human C1q (gC1qR),
Apoptosis, Human cervical squamous carcinoma cellsBackground
Persistent infection with a high-risk human papillomavi-
rus (HPV) type has been correlated with the develop-
ment of cervical cancer [1,2]. HPV 16 is responsible for
over 50% of cervical cancer cases and is the second lar-
gest cause of cancer-related death in women worldwide,
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reproduction in any medium, provided the orwhich includes carcinomas of the vagina, anus, vulva,
penis and oropharynx [3,4]. The HPV 16 genome is
composed of six regulatory proteins (E1, E2, E4, E5, E6,
and E7) that regulate viral life cycle, gene expression,
and cell function [5]. The HPV 16 E2 protein regulates
viral DNA replication and transcription. The papilloma-
virus E2 protein is a 42-kDa nuclear protein containing
two defined functional domains that are relatively con-
served among papillomaviruses [6]. In addition to being
a transcriptional regulator of HPV 16 E6 and E7 in early
stages of the viral lifecycle, the E2 protein has potent
antitumor activity in HPV 16-associated carcinogenesis. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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processes such as cellular proliferation or death, and loss
of E2 gene integrity plays a role in the outcome and local
control of cervical carcinomas [8,9].
Most HPV infections are eliminated through anti-viral
immune responses, and only a percentage of HPV-
infected women with oncogenic types have persistent in-
fections that cause high-grade squamous intraepithelial
lesions [10,11]. Although the immune response to cer-
vical HPV infection is not well understood, recent co-
hort studies have highlighted that cervical HPV infection
affects the maintenance of low cellular protein levels,
changes viral protein expression and inhibits the host’s
immune responses [12,13]. The complement system has
been extensively characterised both biochemically and
functionally. The receptor for the globular heads of C1q
is gC1qR, a ubiquitous and highly anionic 33 kDa cellu-
lar protein that was initially identified as a mitochondrial
matrix protein [14]. Indeed, gC1qR mediates many bio-
logical responses, including inflammation, infection and
immune regulation [15]. Examples of such responses in-
clude phagocytosis and apoptotic cell uptake [16].
In the present study, our aim was to comprehensively
identify cellular genes and biological processes that are
regulated by HPV 16 E2. Our results provide evidence of
an important role for the gC1qR gene in HPV 16 E2-
induced apoptosis of C33a cells.
Materials and methods
Reagents
C33a and SiHa cervical squamous carcinoma cell lines
were obtained from Hangzhou Hibio Bio-tech Co., Ltd
(Hangzhou, Zhejiang, China). The Phototope-HRP
Western Blot Detection System, including anti-mouse
IgGs, HRP-linked antibodies, a biotinylated protein lad-
der, 20× LumiGLO Reagent and 20× peroxide, was pur-
chased from Cell Signaling Technology (Beverly, MA,
USA). The Annexin V-FITC/ Propidium Iodide (PI)
Flow Cytometry Assay Kit was purchased from
Invitrogen (Carlsbad, CA, USA). Antibodies directed
against gC1qR, phosphorylated p38 MAPK (p*-p38
MAPK), phosphorylated JNK (p*-JNK), total p38 MAPK,
total JNK and actin were purchased from Santa Cruz
(Santa Cruz, CA, USA) and Cell Signaling Technology.
pcDNA-HPV 16 E2 and pcDNA-HPV 16 E2 mutant
(mut) plasmids were kindly supplied by Hangzhou Hibio
Bio-tech Co., Ltd. gC1qR small interfering RNA (siRNA)
and negative siRNA (siRNA directed toward an un-
related gene as a negative control) were synthesised
by Wuhan Genesil Biotechnology Co., Ltd (Wuhan,
China). Cell culture supplies were purchased from
Life Technologies (Gaithersburg, MD, USA). Unless
otherwise specified, all of the other reagents were of
analytical grade.C33a And SiHa cell culture and DNA transfection
conditions
C33a and SiHa cells were grown in Dulbecco’s modified
Eagle medium (Gibco BRL, Grand Island, NY, USA),
supplemented with 10% foetal bovine serum, 1% nonessen-
tial amino acids, and 2 mM glutamine. The cells were
maintained in the presence of 5% CO2 at 37°C. Comple-
mentary DNA (cDNA) encoding HPV 16 E2 was cloned in
frame using BamHI/EcoRI sites into the pcDNA 3.1 ex-
pression plasmid (Invitrogen, Carlsbad, CA). The resulting
pcDNA-HPV 16 E2 vector was then transfected into C33a
and SiHa cells. Twenty-four hours after plating, the cells
were serum starved for an additional 24 h to quiescence.
Following serum starvation, the cells were transfected
using Lipofectamine™ reagent (Life Technologies, Inc.)
according to the vendor’s protocol. Briefly, 0.05-1.5 μg/ml
plasmid DNA and 12 μg/ml Lipofectamine™ were diluted
in serum-free DMEM. After incubation for 30 min at 37°C,
DNA-liposome complexes were added dropwise to each
culture dish and incubated at 37°C in a 5% CO2 atmos-
phere for 12 h. Following transfection, the cells were cul-
tured in serum-free DMEM. Reporter gene levels were
normalised to total protein, and each experiment was inde-
pendently performed three to five times.
gC1qR SiRNA-expressing plasmid construction
We designed siRNA to target the 408–426 nucleotide
portion of human gC1qR mRNA; the forward sequence
was 5′-AAC AAC AGC AUC CCA CCA ACA UU-3′. A
gC1qR siRNA-expressing plasmid was constructed using
pGenesil-1 as the vector backbone. BamHI and HindIII
restriction site overhangs were located near the 5′ end
of the two oligonucleotides; a 6-nucleotide poly-T tract
recognised as an RNA pol III termination signal was lo-
cated at the 3′ end of the siRNA template. The siRNA
was synthesised, annealed and ligated into the BamHI
and HindIII restriction sites in the pGenesil-1 expression
vector. A vector containing siRNA for an unrelated gene
was used as a negative control.
Real-time quantitative polymerase chain reaction
(real-time qPCR)
Total RNA was isolated from tissue using Trizol rea-
gent (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instructions. Isolated RNA was then
DNase-treated and reverse-transcribed according to the
manufacturer’s instructions. To detect gC1qR expres-
sion, Primer-F (5′-AAT CAC ACG GTA GAC ACT
GAA ATG CC-3′) and Primer-R (5′-CAT CAT CCC
ATC TAA AAT GTC CCC TG-3′) were used with the
FAM/TAMRA-labelled probe 5′-TGC TCC AGT TCA
ACC AAC GTC CTT CTC-3′. β-actin was quantified
using Primer-F (5′-TCA CCC ACA CTG TGC CCA
TCT ATG A-3′) and Primer-R (5′-CAT CGG AAC
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TAMRA-labelled probe 5′-ACG CGC TCC CCC ATG
CCA TCC TGC GT-3′. Quantitative real-time PCR was
performed using an ABI PRISM 7300 sequence detec-
tion system with the following thermal cycling condi-
tions: 2 min at 50°C and 10 min at 95°C followed by 40
cycles of 15 s at 95°C and 1 min at 60°C. All of the reac-
tions were performed in 50 μL reaction volumes in trip-
licate. Standard curves were generated for gC1qR and
β-actin. The β-actin gene was used as an internal control
in all of the PCR experiments. The relative amounts of
gC1qR mRNA were normalised to β-actin mRNA using
the following formula: 2− ΔΔCT = 2− (CT. gC1qR − CT. actin)
Time × + (CT. gC1qR − CT. actin)Time 0.
Western blot analysis
After various treatments, cells were harvested, pelleted
by short centrifugation and suspended in lysis buffer (10
mM Tris–HCl, pH 7.8, 0.5% sodium deoxycholate, 0.5%
Nonidet P-40, 100 mM NaCl, 10 mM EDTA) sup-
plemented with protease inhibitors for 30 min on ice.
The supernatants were collected by centrifugation at
13,000 × g at 4°C for 15 min. An equal amount of pro-
tein was separated by SDS-PAGE on a 10-15% polyacryl-
amide gel and transferred to a PVDF membrane. The
transferred membranes were blocked for 1 h in 5% non-
fat milk in PBST (PBS containing 0.05% Tween-20), in-
cubated with appropriate primary antibodies followed by
horseradish peroxidase-conjugated secondary antibodies.
The protein bands were visualised using the enhanced
chemiluminescence (ECL) Western Detection System.
Cell viability analysis
The water-soluble tetrazolium salt (WST-1) assay (Roche
Diagnostics, Mannheim, Germany) was performed to as-
sess C33a and SiHa cell viability. The WST-1 assay is a
colorimetric method in which the dye intensity is propor-
tional to the number of viable cells. Cells were seeded into
96-well microtitre plates at a concentration of 5 × 103
cells/well. After 12 h of incubation, cells were treated with
for 48 h. After incubation, the cells were washed with PBS,
WST-1 cell proliferation reagent was added, and the sam-
ples were incubated for 4 h. Sample absorbance was
analysed with a bichromatic ELISA reader at 450 nm. All
of the experiments were performed in triplicate with dif-
ferent C33a and SiHa cell passages.
Cell migration analysis
C33a and SiHa cell (7.5 × 106 cells/mL) migration was
measured using 24 mm diameter chambers with 8 μm
pore filters (Transwell, 6-well cell culture). Cells were
collected and resuspended in serum-free media, and a
0.2 mL cell suspension was added to the upper cham-
bers. Treatment media (0.5 mL) was added to the lowerchambers. The chambers were incubated for 48 h at
37°C in a humidified atmosphere of 5% CO2/95% air.
Next, the filters were fixed in 95% ethanol and stained
with H&E. The upper filter surfaces were scraped twice
with cotton swabs to remove non-migrated cells. Experi-
ments were repeated in triplicate with different passages
of the C33a and SiHa cells, and the migrated cells were
counted microscopically (400 ×) in five different fields
per filter.
Apoptotic cell detection
C33a and SiHa cell apoptosis was detected using the
Annexin V-FITC/propidium iodide (PI) staining kit via
flow cytometry. After different treatments at the indi-
cated times, C33a and SiHa cell were washed and
resuspended in binding buffer (2.5 mM CaCl2, 10 mM
HEPES, pH 7.4, and 140 mM NaCl) before being trans-
ferred to a 5 mL tube. The cells were incubated in the
dark with 5 μL each of Annexin V-FITC and propidium
iodide for 15 min. Binding buffer was then added to
each tube, and the samples were analysed using a
Beckman Coulter Epics XL flow cytometer. Annexin-
V-FITC (−)/PI (−) staining indicated live cells, Annexin-
V-FITC (+)/PI (−) staining indicated cells that were in
the early stages of apoptosis, and Annexin-V-FITC
(+)/PI (+) staining indicated cells that were in the late
stages of apoptosis or necrosis.
Statistical analysis
Most results are presented as the mean ± standard devi-
ation (SD). Differences between data sets were assessed for
significance using Student’s t-test, and a p-value less than
0.05 was considered significant (***p < 0.001; **p < 0.01;
*p < 0.05; #p > 0.05).
Results
The effect of HPV 16 E2 on cervical squamous carcinoma
cell viability, migration and proliferation
To explore the effect of HPV 16 E2 on cervical squa-
mous carcinoma cell viability, C33a and SiHa cells were
assessed using a WST-1 assay following treatment with
unmodified media (control group), empty vector, HPV
16 E2 and a HPV 16 E2 mutant. The data are presented
in Figure 1A; HPV 16 E2 expression decreased cell via-
bility compared with the unmodified media group, while
there was no change in cell viability in the empty vector
or HPV 16 E2 mutant group compared with the un-
modified media group. Cell viability was notably de-
creased in cells transfected with the HPV 16 E2 vector
compared with the empty vector group; moreover, cell
viability was significantly different between the HPV 16
E2 and HPV 16 E2 mutant group.
The number of migrated cells was significantly lower
in cells that were transfected with HPV 16 E2 compared
Figure 1 The effect of HPV 16 E2 on cervical squamous carcinoma cell line (C33a and SiHa) viability, migration and proliferation. Cells
were treated with unmodified media (control), empty vector, HPV 16 E2 and HPV 16 E2 mutant for 48 h. A: C33a and SiHa cell viability was
detected using a WST-1 assay. Sample absorbance was analysed using a bichromatic ELISA reader at 450 nm. **p < 0.01, *p < 0.05, #p > 0.05
versus the control group; ▲▲p < 0.01, ▲p < 0.05 versus the empty vector group. △△p < 0.01, △p < 0.05 versus the HPV 16 E2 group. B: The C33a
and SiHa cell migration was measured with a transwell assay. Migrated cells were counted microscopically (400 X) in five different fields per filter.
**p < 0.01, *p < 0.05, #p > 0.05 versus the control group; ▲▲p < 0.01, ▲p < 0.05 versus the empty vector group. △△△p < 0.001, △p < 0.05 versus
the HPV 16 E2 group. C: C33a and SiHa cell proliferation. 3H-thymidine DNA incorporation results over 18 h of the final incubation. The results are
expressed as the mean ± SD from 3 independent experiments. **p < 0.01, #p > 0.05 versus the control group; ▲▲p < 0.01, ▲p < 0.05 versus the
empty vector group; △△p < 0.01 versus the HPV 16 E2 group.
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grated cells was not different among the empty vector
group, the HPV 16 E2 mutant group and the unmodified
media group (p > 0.05). Transfection of HPV 16 E2 sig-
nificantly reduced the number of migrated cells com-
pared with the empty vector group, whereas HPV 16 E2
mutant transfection significantly increased the number
of migrated cells compared with the HPV 16 E2 vector
group (Figure 1B).
As shown in Figure 1C, cervical squamous carcinoma
cell DNA synthesis was lower in the HPV 16 E2 vector
group than in the unmodified group. However, there
was no difference in cell proliferation among the empty
vector group, the HPV 16 E2 mutant group and the un-
modified media group (p > 0.05). HPV 16 E2 vector
transfection resulted in significantly reduced DNAsynthesis in C33a and SiHa cells compared with the
empty vector group, whereas HPV 16 E2 mutant trans-
fection significantly increased the number of proliferat-
ing cells compared with the HPV 16 E2 vector group.
The effect of HPV 16 E2 on gC1qR expression in cervical
squamous carcinoma cells
To investigate the effect of HPV 16 E2 on gC1qR ex-
pression in cervical squamous carcinoma cell lines, C33a
and SiHa cells were treated with unmodified media (con-
trol group), empty vector, HPV 16 E2 and a HPV 16 E2
mutant. Real-time PCR and Western blot analysis results
demonstrated that the gC1qR expression levels were sig-
nificantly increased in the HPV 16 E2 group compared
with the unmodified media and empty vector groups.
However, gC1qR gene expression in the HPV 16 E2
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in the HPV 16 E2 vector group (Figure 2A-B). These
findings suggest that HPV 16 E2 induces gC1qR gene
expression.
The effect of HPV 16 E2 on gC1qR expression, the p38
MAPK/ JNK signalling pathway and apoptosis in gC1qR-
silenced cervical squamous carcinoma cells
To further explore the effect of HPV 16 E2 on gC1qR
expression, the p38 MAPK/JNK signalling pathway and
apoptosis in gC1qR-silenced cervical squamous carcin-
oma cells (see Additional file 1: Figure S1), C33a and
SiHa cells were treated with unmodified media (control)
or HPV 16 E2 vector. After 72 h, the cells were
transfected with 100 ng of gC1qR siRNA or 100 ng of
negative siRNA. gC1qR gene and protein expressionFigure 2 The effect of HPV 16 E2 on gC1qR expression levels in cervi
treated with unmodified media (control), empty vector, HPV 16 E2 and HPV
demonstrated in C33a and SiHa cells. gC1qR expression levels were analyse
control group; ▲▲▲p < 0.001, ▲▲p < 0.01 versus the empty vector group
protein levels were measured in C33a and SiHa cells using Western blot an
to actin. The results are expressed as the means ± SD of three separate exp
▲▲▲p < 0.001 versus the empty vector group; △△△p < 0.001 versus the HPlevels were analysed by real-time PCR and Western blot
analysis (Figure 3A-B). The results demonstrated that
gC1qR mRNA and protein expression levels were signifi-
cantly increased in the HPV 16 E2 vector group com-
pared with the unmodified media group. However, there
was no difference between the HPV 16 E2 + gC1qR
siRNA group and the unmodified media group (p >
0.05). gC1qR expression in the HPV 16 E2 + gC1qR
siRNA-treated group was significantly lower than that in
the HPV 16 E2 group. In contrast, gC1qR expression
was notably increased in the HPV 16 E2 + negative
siRNA group compared with the HPV 16 E2 + gC1qR
siRNA group.
Phospho-p38 MAPK and phospho-JNK were assessed
by Western blot analysis in cervical squamous carcin-
oma cells that were treated with unmodified mediacal squamous carcinoma cell lines (C33a and SiHa). Cells were
16 E2 mutant for 48 h. A: Relative gC1qR gene expression levels are
d by real-time PCR. ***p < 0.001, **p < 0.01, #p > 0.05 versus the
; △△△p < 0.001, △△p < 0.01 versus the HPV 16 E2 group. B: gC1qR
alysis. The graph depicts relative gC1qR protein levels normalised
eriments. ***p < 0.001, #p > 0.05 versus the control group;
V 16 E2 group.
Figure 3 The effect of HPV 16 E2 on gC1qR expression levels, the p38 MAPK/JNK signalling pathway and apoptosis of gC1qR-silenced
cervical squamous carcinoma cell lines (C33a and SiHa). Cells were treated with unmodified media (control) or HPV 16 E2 vector. After 72 h,
the cells were transfected with 100 ng of gC1qR siRNA or 100 ng of negative siRNA. A: Relative gC1qR gene expression levels were analysed by
real-time PCR. B: gC1qR protein levels were measured using Western blot analysis. The graph depicts the relative gC1qR protein levels normalised
to actin. The results are expressed as the means ± SD of three separate experiments. C: Cells were lysed and examined for p*-p38 and p*-JNK by
Western blot analysis. The graph shows relative phosphorylated p38 MAPK and JNK protein levels normalised to total p38 MAPK and JNK,
respectively. The results are expressed as the means ± SD of three separate experiments. D: Numbers of apoptotic cells were measured by flow
cytometry. The results are expressed as the means ± SD from 3 independent experiments. ***p < 0.001, **p < 0.01, *p < 0.05, #p > 0.05 versus the
HPV 16 E2 (−), gC1qR siRNA (−) and negative siRNA (−) groups; ▲▲▲p < 0.001, ▲▲p < 0.01, ▲p < 0.05 versus HPV 16 E2 (+), gC1qR siRNA (−)
and negative siRNA (−) groups; △△△p < 0.001, △△p < 0.01, △p < 0.05 versus HPV 16 E2 (+), gC1qR siRNA (+) and negative siRNA (−) groups.
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transfected with 100 ng of gC1qR siRNA or 100 ng of
negative siRNA. As shown in Figure 3C, phospho-p38
MAPK and phospho-JNK were significantly increased in
the HPV 16 E2 group and the HPV 16 E2 + negative
siRNA group compared with the unmodified media group.
There was no difference in p*-p38 MAPK and p*-JNKprotein expression between the unmodified media group
and the HPV 16 E2 + gC1qR siRNA group. However, the
phosphorylated p38 MAPK and JNK protein were notably
lower in the HPV 16 E2 + gC1qR siRNA group compared
with the HPV 16 E2 + negative siRNA group (Figure 3C).
C33a and SiHa cell apoptosis was assessed by flow cy-
tometry following treatment with unmodified media
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transfected with 100 ng of gC1qR siRNA or 100 ng of
negative siRNA. The cells were double-stained with
Annexin V and PI. Early and late apoptotic cells were
distributed in the Q1_LR and Q1_UR regions, respect-
ively. Necrotic cells were located in the Q1_UL region.
Figure 3D shows that accumulated HPV 16 E2 increased
the C33a and SiHa cell number in the Q1_LR and
Q1_UR regions in the HPV 16 E2 vector group and the
HPV 16 E2 + negative siRNA group compared with the
unmodified media group. However, the Q1_LR and
Q1_UR regions in the HPV 16 E2 + gC1qR siRNA
vector-transfected cells showed a notable decrease com-
pared with the HPV 16 E2 vector-transfected group.
However, the apoptotic cells in the HPV 16 E2 + gC1qR
siRNA group were significantly decreased compared
with the HPV 16 E2 + negative siRNA group.
The effect of HPV 16 E2 combined with SB203580 or
SP600125 on gC1qR expression and cervical squamous
carcinoma cell viability, migration and proliferation
In these experiments, C33a and SiHa cells were treated
with unmodified media (control) or HPV 16 E2 vector.
After 72 h, the cells were treated with 20 μM SB203580
(a p38 MAPK pathway inhibitor) or 30 μM SP600125
(a JNK pathway inhibitor). gC1qR gene and protein
expression levels were analysed by real-time PCR and
Western blot analysis (Figure 4A-B). The results demon-
strated that the gC1qR mRNA and protein levels were
significantly increased in the HPV 16 E2 vector group
compared with the unmodified media group. However,
there were no differences among the HPV 16 E2 +
SB203580 group, the HPV 16 E2 + SP600125 group and
the unmodified media groups (p > 0.05). In contrast,
gC1qR expression in the HPV 16 E2 + SB203580 group
and the HPV 16 E2 + SP600125 group was notably
reduced compared with the HPV 16 E2 group.
To explore the effect of HPV 16 E2 combined with
SB203580 or SP600125 on cervical squamous carcinoma
cells viability, cells were treated with unmodified media
(control) or HPV 16 E2 vector. After 72 h, the cells were
treated with 20 μM SB203580 (a p38 MAPK pathway in-
hibitor) or 30 μM SP600125 (a JNK pathway inhibitor).
The results demonstrated that HPV 16 E2 decreased cell
viability compared with the unmodified media group.
However, cell viability in the HPV 16 E2 + SB203580
group and the HPV 16 E2 + SP600125 group was not
changed compared with the unmodified media group.
Cell viability was notably increased in cells that were
treated with HPV 16 E2 + SB203580 or HPV 16 E2 +
SP600125 compared with the HPV 16 E2 vector group
(Figure 4C).
HPV 16 E2 transfection caused a significant repression
of migrated cells that was comparable to the unmodifiedmedia group. However, the number of migrated cells
was not different among the HPV 16 E2 + SB203580
group, the HPV 16 E2 + SP600125 group and the un-
modified media group (p > 0.05). Transfection of HPV
16 E2 + SB203580 or HPV 16 E2 + SP600125 signifi-
cantly increased the number of migrated cells compared
with the HPV 16 E2 vector group (Figure 4D).
As shown in Figure 4E, C33a and SiHa cell proliferation
was significantly decreased in HPV 16 E2-transfected cells
compared with the unmodified media group. The num-
bers of proliferating cells were not different among the
HPV 16 E2 + SB203580 group, the HPV 16 E2 +
SP600125 group and the unmodified media group (p >
0.05). Interestingly, transfection of HPV 16 E2 +
SB203580 or HPV 16 E2 + SP600125 increased cell prolif-
eration compared with the HPV 16 E2 vector group.
Discussion
In the present study, we identified gC1qR as a down-
stream target for p38 MAPK/JNK signalling in HPV 16
E2-induced cervical squamous carcinoma cell apoptosis.
Our analysis provided experimental evidence that silen-
cing the gC1qR gene or inhibiting p38 MAPK/JNK sig-
nalling is essential for the in vitro growth and migration
properties of cervical squamous carcinoma cells in re-
sponse to HPV 16 E2 treatment.
The C33a cell line was the primary focus of this experi-
ment because C33a cells are negative for HPV DNA and
RNA [17], and they represent a convenient model to study
the effects of HPV 16 E2 on cellular gene expression with-
out the involvement of other HPV types. Traditionally, the
effects observed in regulating cellular genes when E2 pro-
tein is expressed in cervical carcinoma-derived cell lines
result from repressed expression of the viral oncogenes E6
and E7; however, in this work, we demonstrated that
HPV16 E2 changes cellular gene expression independently
of viral oncoprotein E6 and E7 regulation.
HPV type 16 is the most prevalent type of HPV
(84.7%), which is in agreement with other studies, while
the frequency of HPV type 18 (3.38%) is very low com-
pared with other ethnic populations [18]. Low-grade
dysplasias with HPV 16 infection demonstrated an in-
creased rate of malignancy progression [19]. HPV-16 E6/
E7 oncoproteins have been demonstrated to cause im-
mortalisation of primary human keratinocytes and are
expressed in malignant cancers [20]. Many studies have
previously reported the ability of the HPV-16 E6/E7
oncoproteins to disrupt the normal process of differenti-
ation of human foreskin keratinocytes [21] by targeting
key tumour suppressors, such as p53 [22] and pRb [23],
resulting in increased levels of cell survival proteins,
such as Akt [24], and disruption of the cell cycle [25].
The HPV E2 protein functions as a repressor or an acti-
vator of early gene transcription, which regulates viral
Figure 4 (See legend on next page.)
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Figure 4 The effect of HPV 16 E2 combined with SB203580 or SP600125 on gC1qR expression, and cervical squamous carcinoma cell
line (C33a and SiHa) viability, migration and proliferation. The cells were treated with unmodified media (control) or HPV 16 E2 vector. After
72 h, the cells were treated with 20 μM SB203580 (a p38 MAPK pathway inhibitor) or 30 μM SP600125 (a JNK pathway inhibitor). A: Relative
gC1qR gene expression levels are shown in C33a and SiHa cervical squamous carcinoma cell lines. gC1qR expression levels were analysed by real-
time PCR. B: gC1qR protein expression levels were measured in C33a and SiHa cells using Western blot analysis. The graph depicts relative gC1qR
protein levels normalised to actin. The results are expressed as the means ± SD of three separate experiments. C: C33a and SiHa cell viability was
detected using a WST-1 assay. Sample absorbance was analysed using a bichromatic ELISA reader at 450 nm. D: C33a and SiHa cell migration
was measured by a transwell assay. Migrated cells were counted via microscopy (400 X) in five different fields per filter. E: C33a and SiHa cell
proliferation. 3H-thymidine DNA incorporation over the last 18 h of the final incubation. The results are expressed as the mean ± SD from 3
independent experiments. ***p < 0.001, **p < 0.01, *p < 0.05, #p > 0.05 versus the HPV 16 E2 (−), SB203580 (−), and SP600125 (−) groups;
▲▲▲p < 0.001, ▲▲p < 0.01, ▲p < 0.05 versus the HPV 16 E2 (+), SB203580 (−), and SP600125 (−) groups.
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the viral E2-gene, which controls the transcription of on-
cogenes E6 and E7 that manipulate the cell cycle and
the ability of apoptosis, has been associated with poor
outcomes. Conversely, the HPV 16 E2 gene acted via
mitochondrial-dependent pathways to control cellular
apoptosis and fate [27]. Among mitochondrial matrix
proteins, gC1qR controls diverse cellular processes, such
as cell growth, differentiation and apoptosis [28]. The
present study provides an essential framework for
assessing the role of gC1qR protein in HPV 16 E2-
transfected cervical squamous carcinoma cell apoptosis.
gC1qR is a multi-compartmental and multi-functional
cellular protein that is distributed in several tissues and
cell types, including lymphocytes, endothelial cells, den-
dritic cells and platelets [29,30]. However, in our experi-
ment, immunohistochemistry demonstrated that gC1qR
expression was significantly decreased in human cervical
squamous cell carcinoma tissues compared with normal
cervical tissues (see Additional file 2: Figure S2). Al-
though gC1qR is not overexpressed in human cervical
squamous cell carcinoma tissues, its expression in-
creased significantly in the HPV16 E2-induced cervical
squamous carcinoma cell line.
During complement activation, the biological re-
sponses mediated by C1q recognise and activate the sig-
nal that triggers the classical complement pathway. C1q
functions as a potent extracellular signal for a wide
range of cells, resulting in inhibition of T cell prolifera-
tion or endothelial cell activation [31]. Additionally, the
C1q-gC1qR complex not only may be involved in innate
and adaptive immunity [32], but also may be an under-
lying molecular mechanism in virus infection. Xu et al.
[33] provided evidence that viruses use host gC1qR pro-
tein to inhibit antiviral responses and to promote viral
proliferation by activating a suppressive pathway to
negatively regulate antiviral signalling. When constitu-
tively expressed in a normal murine fibroblast cell line,
gC1qR induces growth perturbation, morphological ab-
normalities and apoptosis [34]. gC1qR has been exten-
sively studied previously as an inducer of apoptosis [35].
Recent cohort studies have shown that gC1qR isa conserved eukaryotic multifunctional protein that
primarily localised in the mitochondrial matrix (see
Additional file 3: Figure S3) and on the cell surface [36].
Human gC1qR is expressed as a proprotein of 282
amino acids (aa) whose first 73 amino acids, containing
a mitochondrial localization signal, are required for lo-
calizing the protein to the mitochondria and are subse-
quently cleaved to generate mature gC1qR. The mature
form of gC1qR has been tied to apoptosis and autophagy
via inducing mitochondrial dysfunction [37]. In the
present study, we determined that silencing the gC1qR
gene in cervical squamous carcinoma cells results in de-
creased cervical squamous carcinoma cell apoptosis
rates.
In the present study, our results indicate that gC1qR is
a physiological inhibitor of HPV 16-induced cervical
squamous carcinoma cell survival. A role for gC1qR in
HPV 16 E2 oncogene-mediated apoptosis was also dem-
onstrated. As shown in Figure 3D, flow cytometry ana-
lysis revealed that cells in the subG1 region decreased
after gC1qR siRNA vector treatment. Interestingly, we
observed that the gC1qR gene has an effect on the p38
MAPK/JNK-pathway in HPV 16 E2 expression. Recently,
it was reported that the p38 MAPK/JNK-pathway is acti-
vated by HPV 16 E6 and E7 viral oncogene expression
[38]. However, our observations suggest that HPV 16 E2
also activates this pathway; however, the consequences
of this activation may be different from the activation in-
duced by the viral oncogenes because tight regulation
and controlled coordination of the p38 MAPK/JNK sig-
nalling cascade is required to maintain the balance be-
tween apoptosis and differentiation.
Conclusion
In this work, our results demonstrate that HPV 16 E2
regulates cellular gene expression independently of the
viral oncoproteins E6 and E7. The data presented in this
study demonstrate that E2 predominantly up-regulates
gC1qR gene expression, which induces cervical cancer
cell apoptosis. The expression of HPV 16 E2 by cells
suggests that increased gC1qR levels are important in
cervical squamous carcinoma cell apoptosis and that
Gao et al. Journal of Translational Medicine 2013, 11:118 Page 10 of 11
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signalling pathway in human cervical squamous carcin-
oma cells.
Additional files
Additional file 1: Figure S1. The levels of gC1qR expression. C33a and
SiHa cells were treated with plain medium (control), negative siRNA and
gC1qR siRNA for 48 h. The expression of the gC1qR protein was measured
by Western blot analysis. The graph depicts the relative gC1qR protein levels
normalised to actin. The results are expressed as the mean ± SD of three
separate experiments. * p < 0.05, #p > 0.05 versus the plain medium group.
Additional file 2: Figure S2. The results of immunohistochemical
staining. The positive results for gC1qR antigen in human cervical tissues
by immunohistochemistry (× 200). A: staining of monoclonal anti-gC1qR
antibody in human cervical squamous cells carcinoma tissues; B: staining
of monoclonal anti-gC1qR antibody in normal cervix tissues.
Additional file 3: Figure S3. The subcellular localization of gC1qR
protein in C33a cells. In this experiment, the intracellular localisation of
gC1qR was detected by cellular fractionation. The C33a cells were separated
into endoplasmic reticulum (ER), nuclei (Nu), and mitochondrial (Mt)
fractions. Calnexin, histone H1 and mtSSB were detected by western
blotting as markers for endoplasmic reticulum, nuclei and mitochondria,
respectively. The expression of gC1qR protein was detected in endoplasmic
reticulum (ER), nuclei (Nu) and mitochondria (Mt) in C33a cells. The
expression of gC1qR protein was localised to the mitochondrial fraction.
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